ASPECTS OF DETECTING PATIENTS WITH FAMILY HYPERCHOLESTEROLEMIA

Cover Page

Cite item

Full Text

Abstract

The review presents current data regarding the etiology and epidemiology of familial hypercholesterolemia (FH), algorithms for identifying patients with FH using clinical scales, genetic testing, cascade screening. The current tactics of treatment of family hypercholesterolemia, including in children and pregnant women, are given.

About the authors

P M Kurbanismailova

ФГБУ Национальный медицинский исследовательский центр кардиологии МЗ РФ

Email: p.kurbanismailova@mail.ru
аспирант отдела проблем атеросклероза ФГБУ “НМИЦК” МЗ РФ

A B Popova

ФГБУ Национальный медицинский исследовательский центр кардиологии МЗ РФ

Email: anna.b.popova@gmail.com
аспирант отдела проблем атеросклероза ФГБУ “НМИЦК” МЗ РФ

N Yu Dranenko

СП “Кардиологический диспансер” ГБУЗ РК «РКБ имени Н.А. Семашко»

Email: nup-d@yandex.ru
врач-кардиолог 3-го кардиологического отделения СП “Кардиологический диспансер” ГБУЗ РК «РКБ имени Н.А. Семашко»

I V Sergienko

ФГБУ Национальный медицинский исследовательский центр кардиологии МЗ РФ

Email: igorcardio@mail.ru
доктор медицинских наук, ведущий научный сотрудник отдела проблем атеросклероза ФГБУ “НМИЦК” МЗ РФ

References

  1. Müller C. Xanthomata, Hypercholesterolemia, Angina Pectoris. Acta Med Scand 1938; 95(S89): 75-84.
  2. Khachadurian A.K. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37(3): 402-407.
  3. Fredrickson D.S., Lees R.S. Editorial: A System for Phenotyping Hyperlipoproteinemia. Circulation 1965; 31(3): 321-327.
  4. Goldstein J.L., Brown M.S. Familial Hypercholesterolemia: Identification of a Defect in the Regulation of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Activity Associated with Overproduction of Cholesterol. Proceedings of the National Academy of Sciences 1973; 70(10): 2804-2808.
  5. Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. М. 2017.
  6. Kontula K., Koivisto U.M., Koivisto P., et al. Molecular Genetics of Familial Hypercholesterolaemia: Common and Rare Mutations of the Low Density Lipoprotein Receptor Gene. Annals of Medicine 1992; 24(5): 363-367.
  7. Seftel H.C., Baker S.G., Jenkins T., et al. Prevalence of familial hypercholesterolemia in Johannesburg Jews. American Journal of Medical Genetics 1989; 34(4): 545-547.
  8. Benn M., Watts G.F., Tybjaerg-Hansen A., et al. Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. The Journalof Clinical Endocrinology & Metabolism 2012; 97(11): 3956-3964.
  9. Pijlman A.H., Huijgen R., Verhagen S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209(1): 189-194.
  10. Vuorio A., Kuoppala J., Kovanen P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2014.
  11. Versmissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337(nov11 1): a2423-a2423.
  12. Аншелес А.А., Шульгин Д.Н., Соломяный В.В. и др. Сопоставление результатов нагрузочных проб, данных однофотонной эмиссионной компьютерной томографии миокарда и коронарографии у больных ишемической болезнью сердца. Кардиологический вестник 2012; VII(2): 10-16.
  13. Аншелес А.А., Халикова Э.И., Рыжикова О.А. Способ количественной оценки нарушений перфузии миокарда по данным однофотонной эмиссионной компьютерной томографии. Медицинская физика 2016; 69(1): 46-53.
  14. Сергиенко В.Б., Аншелес А.А. Томографические методы в оценке перфузии миокарда. Вестник рентгенологии и радиологии 2010; 3: 10-14.
  15. Аншелес А.А., Сергиенко В.Б. Томографические методы диагностики при оценке перфузии миокарда у больных с ишемической болезнью сердца. Медицинская радиология и радиационная безопасность 2011; 56(3): 74-79.
  16. Аншелес А.А., Мартиросян Л.А., Сергиенко И.В. и др. Новые подходы к количественной оценке начальных нарушений и неоднородности перфузии миокарда по данным однофотонной эмиссионной компьютерной томографии. Вестник рентгенологии и радиологии 2015; 5: 17-26.
  17. Marks D., Thorogood M., Neil H.A.W., et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168(1): 1-14.
  18. Umans-Eckenhausen M.A.W., Defesche J.C., Sijbrands E.J.G., et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. The Lancet 2001; 357(9251): 165-168.
  19. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72(2): 171-176.
  20. Teramoto T., Sasaki J., Ishibashi S., et al. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan. JAT 2013; 20(6): 517-523.
  21. Сафарова М.С., Сергиенко И.В., Ежов М.В. и др. Российская научно-исследовательская программа по своевременной диагностике и лечению больных семей- ной гиперхолестеринемией: обоснование и дизайн российского регистра семейной гиперхолестеринемии (РоСГХС). Атеросклероз и дислипидемии 2014; 3: 7-15.
  22. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology 2011; 5(3): 133-140.
  23. WattsG.F.,SullivanD.R.,PoplawskiN.,etal.Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements 2011; 12(2): 221-263.
  24. Ghosh S.K., Majumder B., Dutta A. Tuberous Xanthoma as a Presenting Feature of Familial Homozygous Hypercholesterolemia with Aortic Regurgitation. J Pediatr 2015; 166(1): 198-198.e191.
  25. Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия. Современные аспекты диагностики, профилактики и терапии. Кардиология 2009; 1: 76-83.
  26. Humphries S.E., Norbury G., Leigh S., et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008; 19(4): 362-368.
  27. Soutar A.K., Naoumova R.P. Mechanisms of Disease: genetic causes of familial hypercholesterolemia. Nature Clinical Practice Cardiovascular Medicine 2007; 4(4): 214-225.
  28. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-3490.
  29. Taylor A., Wang D., Patel K., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2009; 77(6): 572-580.
  30. Motazacker M.M., Pirruccello J., Huijgen R., et al. Advancesingeneticsshowtheneedforextendingscreening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J 2012; 33(11): 1360-1366.
  31. Ahmad Z., Adams-Huet B., Chen C., et al. Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort. Circulation: Cardiovascular Genetics 2012; 5(6): 666-675.
  32. Fahed A.C., Nemer G.M. Familial Hypercholesterolemia: The Lipids or the Genes? Nutrition & Metabolism 2011; 8(1): 23.
  33. Seidah N.G. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies. CPD 2013; 19(17): 3161-3172.
  34. Bell D.A., Pang J., Burrows S., et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis 2015; 239(1): 93-100.
  35. Ademi Z., Watts G.F., Pang J., et al. Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. Journal of Clinical Lipidology 2014; 8(4): 390-400.
  36. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009; 17(6): 720-721.
  37. George R., Kovak K., Cox S.L. Aligning Policy to Promote Cascade Genetic Screening for Prevention and Early Diagnosis of Heritable Diseases. J Genet Couns 2015; 24(3): 388-399.
  38. Daniels S.R., Gidding S.S., de Ferranti S.D. Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S30-S37.
  39. van der Graaf A., Avis H.J., Kusters D.M., et al. Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children. Circulation 2011; 123(11): 1167-1173.
  40. Wiegman A. Family History and Cardiovascular Risk in Familial Hypercholesterolemia: Data in More Than 1000 Children. Circulation 2003; 107(11): 1473-1478.
  41. Kusters D.M., de Beaufort C., Widhalm K., et al. Paediatric screening for hypercholesterolaemia in Europe: Table 1. Archives of Disease in Childhood 2011; 97(3): 272-276.
  42. McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr Opin Lipidol 2012; 23(6): 525-531.
  43. Descamps O.S., Tenoutasse S., Stephenne X., et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218(2): 272-280.
  44. Braamskamp M.J.A.M., Kusters D.M., Avis H.J., et al. Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence. Pediatric Drugs 2015; 17(2): 159-166.
  45. Avis H.J., Hutten B.A., Gagné C., et al. Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. J Am Coll Cardiol 2010; 55(11): 1121-1126.
  46. Stein E.A. Statins and Children: Whom Do We Treat and When? Circulation 2007; 116(6): 594-595.
  47. Vuorio A., Kuoppala J., Kovanen P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2010.
  48. Rodenburg J., Vissers M.N., Wiegman A., et al. Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better. Circulation 2007; 116(6): 664-668.
  49. Jansen A.C.M., Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256(6): 482-490.
  50. Oosterveer D.M., Versmissen J., Schinkel A.F.L., et al. Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. Clinical Lipidology 2010; 5(2): 189-197.
  51. McCrindle B.W., O’Neill M.B., Cullen-Dean G., et al. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: A randomized, crossover trial. J Pediatr 1997; 130(2): 266-273.
  52. Tonstad S., Knudtzon J., Sivertsen M., etal. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129(1): 42-49.
  53. Perry C.M. Colesevelam. Pediatric Drugs 2010; 12(2): 133-140.
  54. Goldberg A.C. Novel therapies and new targets of treatment for familial hypercholesterolemia. Journal of Clinical Lipidology 2010; 4(5): 350-356.
  55. Hopkins P.N., Toth P.P., Ballantyne C.M., et al. Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S9-S17.
  56. Ito M.K., McGowan M.P., Moriarty P.M. Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S38-S45.
  57. Klingel R., Gohlen B., Schwarting A., et al. Differential Indication of Lipoprotein Apheresis During Pregnancy. Therapeutic Apheresis and Dialysis 2003; 7(3): 359-364.
  58. Basaran A. Pregnancy-induced hyperlipopro- teinemia: review of the literature. Reprod Sci 2009; 16(5): 431-437.
  59. De Assis S.M., Seguro A.C., Helou C.M. Effects of maternal hypercholesterolemia on pregnancy and development of offspring. Pediatr Nephrol 2003; 18(4): 328-334.
  60. Thadhani R., Stampfer M.J., Hunter D.J., et al. High Body Mass Index and Hypercholesterolemia. Obstetrics & Gynecology 1999; 94(4): 543-550.
  61. Hameed A.B., Tummala P.P., Goodwin T.M., et al. Unstable angina during pregnancy in two patients with premature coronary atherosclerosis and aortic stenosis in association with familial hypercholesterolemia. Am J Obstet Gynecol 2000; 182(5): 1152-1155.
  62. Youngblom E., Knowles J.W. Familial Hypercholesterolemia. In: Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., et al., editors. GeneReviews(R). Seattle (WA)1993.
  63. Harada-Shiba M., Arai H., Oikawa S., et al. Guidelines for the Management of Familial Hypercholesterolemia. JAT 2012; 19(12): 1043-1060.
  64. Anedda S., Mura S., Marcello C., et al. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. Transfusion and Apheresis Science 2011; 44(1): 21-24.
  65. Beigel Y., Bar J., Cohen M., et al. Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange. Acta Obstetricia et Gynecologica Scandinavica 1998; 77(6): 603-608.
  66. Fahed A., Nassar A. Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis. Am J Perinatol Rep 2012; 02(01): 033-036.
  67. Mabuchi H., Sakai Y., Watanabe A., et al. Normalization of low-density lipoprotein levels and disappearance of xanthomas during pregnancy in a woman with heterozygous familial hypercholesterolemia. Metabolism 1985; 34(4): 309-315.
  68. Shiomi M., Ito T., Watanabe Y. Increase in hepatic low-density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipidemic rabbits; an animal model for familial hypercholesterolemia. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1987; 917(1): 92-100.

Copyright (c) 2017 Kurbanismailova P.M., Popova A.B., Dranenko N.Y., Sergienko I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies